| Literature DB >> 1664187 |
K W Mollison1, T A Fey, R A Krause, L Miller, R P Edalji, R G Conway, W Mandecki, M A Shallcross, M Kawai, Y S Or.
Abstract
A number of C5a modifications were tested to determine effects on receptor binding to polymorphonuclear leukocyte (PMNL) membrane receptors and triggering of PMNL chemokinesis and myeloperoxidase (MPO) release. Site-directed mutagenesis was used to probe relationships of key C-terminal residues, and suggested a role for additional sites, particularly Lys19-20. A synthetic peptide based on C5a 19-30, weakly inhibited C5a binding. Potency of the C-terminal octapeptide, a full agonist, was markedly improved by a single Phe substitution for His67, and a Phe point mutation at this site was shown to enhance activity of the full recombinant protein.Entities:
Mesh:
Substances:
Year: 1991 PMID: 1664187
Source DB: PubMed Journal: Agents Actions Suppl ISSN: 0379-0363